InVivo Therapeutics (NASDAQ:NVIV) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of InVivo Therapeutics (NASDAQ:NVIV – Free Report) in a research report report published on Saturday. The firm issued a sell rating on the biotechnology company’s stock. InVivo Therapeutics Stock Performance NASDAQ NVIV opened at $0.71 on Friday. InVivo Therapeutics has a 1-year low of $0.60 and a 1-year high of […]

Related Keywords

United States , ,Invivo Therapeutics Holdings Corp ,Citadel Advisors ,Invivo Therapeutics Company Profile ,Renaissance Technologies ,Vanguard Group Inc ,Invivo Therapeutics ,Free Report ,Vivo Therapeutics ,Get Free Report ,Sigma Advisers ,Sigma Investments ,Vivo Therapeutics Holdings ,Neuro Spinal Scaffold ,Invivo Therapeutics Daily ,Nasdaq Nviv ,Enviv ,Medical ,Initiated Coverage ,Stocknews Com ,